CompletedNCT04448561
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
Medication studyAges 18–60United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Overland ParkSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 30, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 24
- Sponsor
- Astellas Pharma Global Development, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT04448561
- Official title
Show the full official title
A Phase 1 Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants
Get this study by email
Recruitment & locations
CompletedOverland Park
Questions about this study
Who is behind this study?
The study sponsor is Astellas Pharma Global Development, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including ASP8082, morphine and Placebo.
Who was this study for?
Listed age limits: 18 years to 60 years.
